Evidence map›Paper›PMID 33143119›Full record

ArticleAntioxidants (Basel, Switzerland)2020

Disrupted Mitochondrial and Metabolic Plasticity Underlie Comorbidity between Age-Related and Degenerative Disorders as Parkinson Disease and Type 2 Diabetes Mellitus.

Diana Luz Juárez-Flores, Mario Ezquerra, Ïngrid Gonzàlez-Casacuberta, Aida Ormazabal, Constanza Morén, Eduardo Tolosa, Raquel Fucho, Mariona Guitart-Mampel, Mercedes Casado, Francesc Valldeoriola and 13 more

Open access · goldAbstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.8field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 4 institutions in 2 countries.

Diana Luz Juárez-FloresLaboratory of Muscle Research and Mitochondrial Function, Department of Internal Medicine-Hospital Clínic of Barcelona (HCB), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Science, University of Barcelona (UB), 08036 Barcelona, Spain.
Mario EzquerraLaboratory of Parkinson Disease and Other Neurodegenerative Movement Disorders, IDIBAPS, Institut de Neurociències, UB, 08036 Barcelona, Spain.
Ïngrid Gonzàlez-CasacubertaLaboratory of Muscle Research and Mitochondrial Function, Department of Internal Medicine-Hospital Clínic of Barcelona (HCB), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Science, University of Barcelona (UB), 08036 Barcelona, Spain.
Aida OrmazabalCentro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras (CIBERER), 28029 Madrid, Spain.
Constanza MorénLaboratory of Muscle Research and Mitochondrial Function, Department of Internal Medicine-Hospital Clínic of Barcelona (HCB), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Science, University of Barcelona (UB), 08036 Barcelona, Spain.
Eduardo TolosaLaboratory of Parkinson Disease and Other Neurodegenerative Movement Disorders, IDIBAPS, Institut de Neurociències, UB, 08036 Barcelona, Spain.
Raquel FuchoDepartment of Cell Death and Proliferation, Instituto de Investigaciones Biomédicas de Barcelona (IIBB), Consejo Superior Investigaciones Científicas (CSIC), 08001 Barcelona, Spain.
Mariona Guitart-MampelLaboratory of Muscle Research and Mitochondrial Function, Department of Internal Medicine-Hospital Clínic of Barcelona (HCB), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Science, University of Barcelona (UB), 08036 Barcelona, Spain.
Mercedes CasadoCentro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras (CIBERER), 28029 Madrid, Spain.
Francesc ValldeoriolaLaboratory of Parkinson Disease and Other Neurodegenerative Movement Disorders, IDIBAPS, Institut de Neurociències, UB, 08036 Barcelona, Spain.
Joan de la Torre-LaraLaboratory of Muscle Research and Mitochondrial Function, Department of Internal Medicine-Hospital Clínic of Barcelona (HCB), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Science, University of Barcelona (UB), 08036 Barcelona, Spain.
Esteban MuñozLaboratory of Parkinson Disease and Other Neurodegenerative Movement Disorders, IDIBAPS, Institut de Neurociències, UB, 08036 Barcelona, Spain.
Ester TobíasLaboratory of Muscle Research and Mitochondrial Function, Department of Internal Medicine-Hospital Clínic of Barcelona (HCB), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Science, University of Barcelona (UB), 08036 Barcelona, Spain.
Yaroslau ComptaLaboratory of Parkinson Disease and Other Neurodegenerative Movement Disorders, IDIBAPS, Institut de Neurociències, UB, 08036 Barcelona, Spain.
Francesc Josep García-GarcíaLaboratory of Muscle Research and Mitochondrial Function, Department of Internal Medicine-Hospital Clínic of Barcelona (HCB), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Science, University of Barcelona (UB), 08036 Barcelona, Spain.
Carmen García-RuizDepartment of Cell Death and Proliferation, Instituto de Investigaciones Biomédicas de Barcelona (IIBB), Consejo Superior Investigaciones Científicas (CSIC), 08001 Barcelona, Spain.
Jose Carlos Fernandez-ChecaDepartment of Cell Death and Proliferation, Instituto de Investigaciones Biomédicas de Barcelona (IIBB), Consejo Superior Investigaciones Científicas (CSIC), 08001 Barcelona, Spain.
Maria José MartíLaboratory of Parkinson Disease and Other Neurodegenerative Movement Disorders, IDIBAPS, Institut de Neurociències, UB, 08036 Barcelona, Spain.
Josep Maria GrauLaboratory of Muscle Research and Mitochondrial Function, Department of Internal Medicine-Hospital Clínic of Barcelona (HCB), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Science, University of Barcelona (UB), 08036 Barcelona, Spain.
Francesc CardellachLaboratory of Muscle Research and Mitochondrial Function, Department of Internal Medicine-Hospital Clínic of Barcelona (HCB), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Science, University of Barcelona (UB), 08036 Barcelona, Spain.
Rafael ArtuchCentro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras (CIBERER), 28029 Madrid, Spain.
Rubén Fernández-SantiagoLaboratory of Parkinson Disease and Other Neurodegenerative Movement Disorders, IDIBAPS, Institut de Neurociències, UB, 08036 Barcelona, Spain.
Glòria GarrabouLaboratory of Muscle Research and Mitochondrial Function, Department of Internal Medicine-Hospital Clínic of Barcelona (HCB), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Science, University of Barcelona (UB), 08036 Barcelona, Spain.ORCID 0000-0001-8973-9933
Centre for Biomedical Network Research on Rare Diseases · ESBiomedical Research Networking Center on Neurodegenerative Diseases · ESKeck Hospital of USC · USInstitut d'Investigacions Biomèdiques de Barcelona · ES

Funding

Fondo de Investigaciones Sanitarias del ISCIII PI1800451Fondo de Investigaciones Sanitarias del ISCIII PI1800498Fundació Privada Cellex and Suports de Grups de Recerca 2017 SGR 893Integrated Projects of Excellence (PIE) PIE14/00061Maria de Maetzu Unit of Excellence MDM-2017-0729Proyectos I+D+i. Ministerio de Ciencia, Innovación y Universidades (ES) PID2019-111669RB-I00Retos de investigación. Ministerio de Ciencia, Innovación y Universidades (ES) SAF2015-69944-RRetos de investigación. Ministerio de Ciencia, Innovación y Universidades (ES). SAF2017-85877-R
6 · The paper itself

Abstract

Idiopathic Parkinson's disease (iPD) and type 2 diabetes mellitus (T2DM) are chronic, multisystemic, and degenerative diseases associated with aging, with eventual epidemiological co-morbidity and overlap in molecular basis. This study aims to explore if metabolic and mitochondrial alterations underlie the previously reported epidemiologic and clinical co-morbidity from a molecular level. To evaluate the adaptation of iPD to a simulated pre-diabetogenic state, we exposed primary cultured fibroblasts from iPD patients and controls to standard (5 mM) and high (25 mM) glucose concentrations to further characterize metabolic and mitochondrial resilience. iPD fibroblasts showed increased organic and amino acid levels related to mitochondrial metabolism with respect to controls, and these differences were enhanced in high glucose conditions (citric, suberic, and sebacic acids levels increased, as well as alanine, glutamate, aspartate, arginine, and ornithine amino acids;

Indexed as

iPD (idiopathic Parkinson’s disease)metabolomemitochondriaT2DM (type 2 diabetes mellitus)

Identifiers

PMID33143119
PMCPMC7693963
OpenAlexW3094939864

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.